# Semnur Pharmaceuticals, Inc.: financial statements, quarterly

SMNR · OTC · CIK 1913577 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/smnr.md) · [Financials](/companies/smnr/financials.md) · [Filings](/companies/smnr/filings.md) · [Insiders](/companies/smnr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/smnr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | not reported | not reported | [0.2](/filings/0001193125-25-277536.md) | [0.2 d](/filings/0001193125-26-082642.md) | [0.2](/filings/0001193125-26-221896.md) | [0.5](/filings/0001193125-26-342594.md) | [1.1](/filings/0001193125-25-277536.md) | [0.7 d](/filings/0001193125-26-082642.md) | [1.3](/filings/0001193125-26-221896.md) | [1.2](/filings/0001193125-26-342594.md) |
| Operating income | $m | [(0.5)](/filings/0001213900-24-100217.md) | [(0.2) d](/filings/0001213900-25-027319.md) | [(0.4)](/filings/0001213900-25-044889.md) | [(0.2)](/filings/0001213900-25-077047.md) | [(1.3)](/filings/0001193125-25-277536.md) | [(0.8) d](/filings/0001193125-26-082642.md) | [(0.7)](/filings/0001193125-26-221896.md) | [(1.0)](/filings/0001193125-26-342594.md) | [(153)](/filings/0001193125-25-277536.md) | [(6.2) d](/filings/0001193125-26-082642.md) | [(4.6)](/filings/0001193125-26-221896.md) | [(4.2)](/filings/0001193125-26-342594.md) |
| Interest expense | $m | [0.0](/filings/0001213900-23-085292.md) | [0.0 d](/filings/0001213900-25-027319.md) | [0.0](/filings/0001213900-25-044889.md) | [0.0](/filings/0001213900-25-077047.md) | [0.0](/filings/0001213900-24-100217.md) | [0.0 d](/filings/0001213900-25-027319.md) | [0.0](/filings/0001213900-25-044889.md) | [0.0](/filings/0001213900-25-077047.md) | not reported | not reported | not reported | [0.1](/filings/0001193125-26-342594.md) |
| Net income | $m | [0.6](/filings/0001213900-24-100217.md) | [0.6](/filings/0001213900-25-027319.md) | [(1.5)](/filings/0001193125-25-277536.md) | [(1.1)](/filings/0001193125-25-277536.md) | [(1.3)](/filings/0001193125-25-277536.md) | [(0.2)](/filings/0001213900-25-027319.md) | [(0.7)](/filings/0001193125-26-342594.md) | [(1.0)](/filings/0001193125-26-342594.md) | [(153)](/filings/0001193125-25-277536.md) | [(6.2) d](/filings/0001193125-26-082642.md) | [(4.6)](/filings/0001193125-26-342594.md) | [(4.3)](/filings/0001193125-26-342594.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | [(0.01)](/filings/0001193125-25-277536.md) | not reported | [(0.01)](/filings/0001193125-26-221896.md) | [(0.01)](/filings/0001193125-26-342594.md) | [(0.76)](/filings/0001193125-25-277536.md) | not reported | [(0.02)](/filings/0001193125-26-221896.md) | [(0.02)](/filings/0001193125-26-342594.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | [(0.01)](/filings/0001193125-25-277536.md) | not reported | [(0.01)](/filings/0001193125-26-221896.md) | [(0.01)](/filings/0001193125-26-342594.md) | [(0.76)](/filings/0001193125-25-277536.md) | not reported | [(0.02)](/filings/0001193125-26-221896.md) | [(0.02)](/filings/0001193125-26-342594.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001213900-23-085292.md) | [0.2](/filings/0001213900-24-045702.md) | [0.0](/filings/0001213900-24-045702.md) | [0.0](/filings/0001213900-24-070799.md) | [0.0](/filings/0001213900-24-100217.md) | [0.0](/filings/0001193125-26-082642.md) | [0.0](/filings/0001213900-25-044889.md) | not reported | [0.1](/filings/0001193125-25-277536.md) | [0.0](/filings/0001193125-26-342594.md) | [0.1](/filings/0001193125-26-221896.md) | [0.0](/filings/0001193125-26-342594.md) |
| Current assets | $m | [0.0](/filings/0001213900-23-085292.md) | [0.2](/filings/0001213900-25-027319.md) | [0.1](/filings/0001213900-24-045702.md) | [0.0](/filings/0001213900-24-070799.md) | [0.0](/filings/0001213900-24-100217.md) | [6.0](/filings/0001193125-26-082642.md) | [0.0](/filings/0001213900-25-044889.md) | [0.0](/filings/0001213900-25-077047.md) | [0.1](/filings/0001193125-25-277536.md) | [0.6](/filings/0001193125-26-342594.md) | [1.2](/filings/0001193125-26-221896.md) | [1.2](/filings/0001193125-26-342594.md) |
| Total assets | $m | [90.1](/filings/0001213900-23-085292.md) | [50.7](/filings/0001213900-25-027319.md) | [51.3](/filings/0001213900-24-045702.md) | [52.1](/filings/0001213900-24-070799.md) | [8.9](/filings/0001213900-24-100217.md) | [6.7](/filings/0001193125-26-082642.md) | [9.1](/filings/0001213900-25-044889.md) | [0.6](/filings/0001213900-25-077047.md) | [0.8](/filings/0001193125-25-277536.md) | [1.3](/filings/0001193125-26-342594.md) | [2.0](/filings/0001193125-26-221896.md) | [1.9](/filings/0001193125-26-342594.md) |
| Current liabilities | $m | [5.1](/filings/0001213900-23-085292.md) | [5.6](/filings/0001213900-25-027319.md) | [6.0](/filings/0001213900-24-045702.md) | [6.3](/filings/0001213900-24-070799.md) | [6.6](/filings/0001213900-24-100217.md) | [0.0](/filings/0001193125-26-082642.md) | [7.9](/filings/0001213900-25-044889.md) | [8.3](/filings/0001213900-25-077047.md) | [10.0](/filings/0001193125-25-277536.md) | [10.2](/filings/0001193125-26-342594.md) | [10.4](/filings/0001193125-26-221896.md) | [10.7](/filings/0001193125-26-342594.md) |
| Total liabilities | $m | [8.0](/filings/0001213900-23-085292.md) | [8.5](/filings/0001213900-25-027319.md) | [8.9](/filings/0001213900-24-045702.md) | [9.2](/filings/0001213900-24-070799.md) | [9.5](/filings/0001213900-24-100217.md) | [49.5](/filings/0001193125-26-082642.md) | [10.7](/filings/0001213900-25-044889.md) | [11.2](/filings/0001213900-25-077047.md) | [15.4](/filings/0001193125-25-277536.md) | [22.1](/filings/0001193125-26-342594.md) | [27.3](/filings/0001193125-26-221896.md) | [31.6](/filings/0001193125-26-342594.md) |
| Shareholders' equity | $m | [(7.9)](/filings/0001213900-24-100217.md) | [(38.1)](/filings/0001193125-26-082642.md) | [(39.6)](/filings/0001193125-25-277536.md) | [(40.7)](/filings/0001193125-25-277536.md) | [(42.0)](/filings/0001193125-25-277536.md) | [(42.8)](/filings/0001193125-26-342594.md) | [(43.4)](/filings/0001193125-26-342594.md) | [(44.4)](/filings/0001193125-26-342594.md) | [(14.6)](/filings/0001193125-25-277536.md) | [(20.8)](/filings/0001193125-26-342594.md) | [(25.3)](/filings/0001193125-26-342594.md) | [(29.7)](/filings/0001193125-26-342594.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(75.7) d](/filings/0001213900-24-100217.md) | [(159) d](/filings/0001213900-25-027319.md) | [(374)](/filings/0001213900-25-044889.md) | [(115) d](/filings/0001213900-25-077047.md) | [(2,995) d](/filings/0001193125-25-277536.md) | [(1,407) d](/filings/0001193125-26-082642.md) | [(399)](/filings/0001193125-26-221896.md) | [268 d](/filings/0001193125-26-342594.md) | [(2,131) d](/filings/0001193125-25-277536.md) | [(3,605) d](/filings/0001193125-26-082642.md) | [(2,670)](/filings/0001193125-26-221896.md) | [(2,138) d](/filings/0001193125-26-342594.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001213900-25-027319.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [200](/filings/0001193125-25-277536.md) | [200](/filings/0001193125-26-221896.md) | [200](/filings/0001193125-26-342594.md) | [202](/filings/0001193125-25-277536.md) | [230](/filings/0001193125-26-221896.md) | [230](/filings/0001193125-26-342594.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 230,209,142 at 2026-08-10, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342594.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.